# Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

> **NCT04693468** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 111 (estimated)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Recurrent Malignant Solid Neoplasm

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Crizotinib
- **DRUG:** Palbociclib Isethionate
- **DRUG:** Talazoparib Tosylate

## Key facts

- **NCT ID:** NCT04693468
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04693468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04693468, "Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04693468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*